Merrill reiterates New River at buy

New River Pharmaceuticals Inc. was reiterated at a buy rating by Merrill Lynch analyst David Munno. The Food and Drug Administration advisory panel on cardiovascular risks and ADHD drugs was primarily as expected. The committee was split 8-7 to move risk of therapeutic use of stimulants to a black box warning. Given the more cautious nature of the FDA recently, it would not be surprising to see at least a medication guide for physicians and patients on cardiovascular risks. Shares of the Radford, Va., pharmaceutical company were down $1.45, or 4.52%, at $30.62 on volume of 370,508 shares versus the three-month running average of 269,206 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.